PERSPECTIVES OF PHARMACOLOGICAL THERAPY USE IN NEUROREHABILITATION
- Authors: Shishkova V.N.1, Remennik A.I.2, Kerimova E.I.2, Zotova L.I.2, Maliukova N.G.2
-
Affiliations:
- Yevdokimov Moscow State University of Medicine and Dentistry
- Center for Speech Pathology and Neurorehabilitation
- Issue: Vol 22, No 2 (2020)
- Pages: 24-28
- Section: Articles
- URL: https://journal-vniispk.ru/2075-1753/article/view/95187
- DOI: https://doi.org/10.26442/20751753.2020.2.200016
- ID: 95187
Cite item
Full Text
Abstract
Aim.To study dynamics of neural cell adhesion molecules (NCAM), brain-derived neurotrophic factor (BDNF), and N-methyl-D-aspartate (NMDA) receptor NR2-subunit antibodies in patients after first ischemic stroke at the background of using medication Ipigrix in dosage 60 mg per day in addition to standard neurorehabilitation complex. Materials and methods. The study included 45 patients aged 60 to 85 years at the moment of first ischemic stroke. Neurorehabilitation complex was performed for 21 days and included background therapy, everyday individual and group sessions with speech pathologists and neuropsychologists, rehabilitation exercise therapy, massage therapy, and physiotherapeutic procedures. Patients were randomized in two groups using envelopes method. Group 1 included 30 patients for whom Ipigrix in dosage 20 mg per day was added to standard neurorehabilitation complex, therapy duration was 21 days. Group 2 included 15 patients who received standard neurorehabilitation complex without Ipigrix intake. In every patient included in the study NCAM, BDNF, and NMDA receptor NR2-subunit antibodies testing was performed twice. Results. During neurorehabilitation treatment in group of patients receiving Ipigrix in dosage 60 mg per day BDNF concentration increased significantly in group 1 (p=0.002), while in group 2 no significant changes were observed. Study of neurotrophic function marker BDNF concentration dynamics (А) showed 2.1 (0.5; 2.5) ng/ml in group 1; and -1.1 (-2.9; 0.6) ng/ml in group 2. These changes were considered significant (p=0.003). NCAM concentration significantly decreased in group 1 (p=0.005), while in group 2 no significant changes were observed. Study of neural cell adhesion molecules concentration dynamics (А) showed -0.56 (-1.72; 0.06) ng/ml in group 1, and - 0.65 (-0.19; 3.00) ng/ml in group 2, these changes were considered significant (p=0.002). In our study no significant changes in NMDA receptor NR2-subunit antibodies were observed in both groups. Conclusions. Use of medication Ipigrix in dosage 60 mg per day in addition to standard neurorehabilitation complex in patients after first ischemic stroke results in significant changes in neuroplasticity markers concentration that allows to perform more effective neurorehabilitation treatment.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Veronika N. Shishkova
Yevdokimov Moscow State University of Medicine and Dentistry
Email: veronika-1306@mail.ru
канд. мед. наук, ст. науч. сотр., врач-эндокринолог
Alla Iu. Remennik
Center for Speech Pathology and Neurorehabilitationканд. мед. наук, зав. клинико-биохимической лаб.
Elena I. Kerimova
Center for Speech Pathology and Neurorehabilitationврач-лаборант клинико-биохимической лаб.
Lubov I. Zotova
Center for Speech Pathology and Neurorehabilitationврач-невролог, зав. неврологическим стационаром
Natalia G. Maliukova
Center for Speech Pathology and Neurorehabilitationканд. психол. наук, зав. отд-нием клинической психологии
References
- Гусев Е.И., Скворцова В.И., Стаховская Л.В. Проблема инсульта в Российской Федерации: время активных совместных действий. Журн. неврологии и психиатрии. 2007; 8: 4-10. @@Gusev E.I., Skvortsova V.I., Stakhovskaia L.V. Problema insul'ta v Rossiiskoi Federatsii: vremia aktivnykh sovmestnykh deistvii. Zhurn. nevrologii i psikhiatrii. 2007; 8: 4-10 (in Russian).
- Скворцова В.И. Принципы ранней реабилитации больных с инсультом. Инсульт (Прил. к Журн. неврологии и психиатрии. 2002; 7: 28-33. @@Skvortsova V.I. Printsipy rannei reabilitatsii bol'nykh s insul'tom. Insul't (Pril. k Zhurn. nevrologii i psikhiatrii. 2002; 7: 28-33 (in Russian).
- Burns MS. Application of Neuroscience to Technology in Stroke Rehabilitation. Top Stroke Rehabil 2008; 15: 570-9.
- Кадыков А.С., Черникова Л.А., Шахпаронова В.Н. Реабилитация неврологических больных. М.: МЕДпресс-информ, 2008. @@Kadykov A.S., Chernikova L.A., Shakhparonova V.N. Rehabilitation of neurological patients. Moscow: MED-press-inform, 2008 (in Russian).
- Шишкова В.Н., Зотова Л.И., Малюкова Н.Г. и др. Оценка влияния терапии церебролизином у пациентов с постинсультной афазией на уровень BDNF в зависимости от наличия или отсутствия нарушений углеводного обмена. Журн. неврологии и психиатрии им. С.С. Корсакова. 2015; 5: 57-63.
- Шишкова В.Н, Зотова Л.И., Кан Н.В. и др. Оценка эффективности нафтидрофурила в составе ранней комплексной реабилитации у пациентов с постинсультной афазией. Врач. 2017; 7: 47-50. @@Shishkova V.N, Zotova L.I., Kan N.V. et al. Otsenka effektivnosti naftidrofurila v sostave rannei kompleksnoi reabilitatsii u patsientov s postinsul'tnoi afaziei. Vrach. 2017; 7: 47-50 (in Russian).
- Лукъянюк Е.В., Шкловский В.М., Малюкова Н.Г. Опыт применения акатинола мемантина в резидуальном периоде инсульта. Журн. неврологии и психиатрии. 2010; 12: 28-33. @@Luk"ianiuk E.V., Shklovskii V.M., Maliukova N.G. Opyt primeneniia akatinola memantina v rezidual'nom periode insul'ta. Zhurn. nevrologii i psikhiatrii. 2010; 12: 28-33 (in Russian).
- Гомазков О.А. Нейротрофические и ростовые факторы мозга: регуляторная специфика и терапевтический потенциал. Успехи физиологических наук. 2005; 36 (2): 1-25. @@Gomazkov O.A. Neirotroficheskie i rostovye faktory mozga: reguliatornaia spetsifika i terapevticheskii potentsial. Uspekhi fiziologicheskikh nauk. 2005; 36 (2): 1-25 (in Russian).
- Шишкова В.Н., Зотова Л.И., Малюкова Н.Г. и др. Новые возможности в медикаментозной терапии постинсультной афазии. Лечащий врач. 2019; 2: 64-9. @@Shishkova V.N., Zotova L.I., Maliukova N.G. et al. Novye vozmozhnosti v medikamentoznoi terapii postin-sul'tnoi afazii. Lechashchii vrach. 2019; 2: 64-9 (in Russian).
- Катунина Е.А. Применение ипидакрина в восстановительном периоде ишемического инсульта. Рус. медицинский журн. 2008; 16 (12): 1-6. @@Katunina E.A. Primenenie ipidakrina v vosstanovitel'nom periode ishemicheskogo insul'ta. Rus. meditsinskii zhurn. 2008; 16 (12): 1-6 (in Russian).
- Гомазков О.А. Нейротрофические и ростовые факторы мозга: регуляторная специфика и терапевтический потенциал. В сб.: Успехи физиологических наук. 2005; 36 (2): 1-25. @@Gomazkov O.A. Neirotroficheskie i rostovye faktory mozga: reguliatornaia spetsifika i terapevticheskii potentsial. V sb.: Uspekhi fiziologicheskikh nauk. 2005; 36 (2): 1-25 (in Russian).
- Fantacci C, Capozzi D, Ferrara P, Chiaretti A. Neuroprotective role of nerve growth factor in hypoxic-ischemic brain injury. Brain Sci 2013; 3 (3): 1013-22.
- Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors 2004; 22 (3): 123-31.
- Berezin V, Bock E, Poulsen FM. The neural cell adhesion molecule. Cur Opin Drug Dis Dev 2000; 3: 605-9.
- Fox GB, Kjoller C, Murphy KJ, Regan CM. The modulations of NCAM polysialylation state that follow transient global ishemia are brief on neurons but enduring on glia. J Neuropathol Exp Neurol 2001; 60 (2): 132-40.
- Hashiguchi T, Tara M, Niina K et al. Adult T-cell leukemia cells which express neural cell adhesion molecule (NCAM) and infiltrate into the central nervous system. Intern Med 2002; 41 (1): 34-8.
- Скоромец А.А., Дамбинова С.А., Дьяконов М.М. и др. Новые биомаркеры поражений мозга. Нейроиммунология. 2009; 7 (2): 18-23. @@Skoromets A.A., Dambinova S.A., D'iakonov M.M. et al. Novye biomarkery porazhenii mozga. Neiroimmunologiia. 2009; 7 (2): 18-23 (in Russian).
- Weissman JD, Khunteev GA, Heath R, Dambinova SA. NR2 antibodies: risk assessment of transient ischemic attack (TIA)/stroke in patients with history of isolated and multiple cerebrovascular events. J Neurol Sci 2011; 300: 97-102.
Supplementary files
